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Low bone mineral density (BMD) in adolescents with anorexia
nervosa (AN) is associated with a low bone turnover state.
Osteoprotegerin (OPG), a cytokine that acts as a decoy recep-
tor for receptor activator of nuclear factor-B ligand , de-
creases bone resorption by inhibiting differentiation of oste-
oclast precursors and activation of mature osteoclasts, and by
stimulating osteoclast apoptosis. We compared OPG levels in
43 adolescent girls with AN with 38 controls and examined
bone density, bone turnover, and hormonal parameters. Girls
with AN had lower fat mass, lean body mass, lumbar BMD
z-scores, and lumbar bone mineral apparent density than con-
trols. OPG levels were higher in girls with AN than in controls
(44.5  22.5 pg/ml vs. 34.5  12.7 pg/ml, P  0.02). Osteocalcin,
deoxypyridinoline, estradiol, free testosterone, IGF-I, and lep-
tin were lower in AN than in healthy adolescents. OPG values
correlated negatively with body mass index (r  0.27, P 
0.02), percent fat mass (r0.35, P 0.0002), leptin (r0.28,
P  0.02), lumbar BMD z-scores (r  0.25, P  0.03), and
lumbar bone mineral apparent density (r0.26, P 0.03). In
conclusion, adolescent girls with AN have higher serum OPG
values than controls. OPG values correlate negatively with
markers of nutritional status and lumbar bone density
z-scores and may be a compensatory response to the bone loss
seen in this population. (J Clin Endocrinol Metab 88:
3816–3822, 2003)
OSTEOPROTEGERIN (OPG) AND RANKL [receptor ac-tivator of nuclear factor-B (RANK) ligand] have been
identified and recognized as important regulators of bone
resorption (reviewed in Refs. 1 and 2). RANK (the receptor
for RANKL) is a type I transmembrane protein of the TNF
receptor superfamily and is expressed on osteoclast precur-
sors, whereas RANKL, a cell-bound polypeptide, is ex-
pressed on the cell surface of osteoblasts. When RANK rec-
ognizes and binds to RANKL through cell-cell interactions,
osteoclast precursors differentiate into mature osteoclasts,
resulting in increased bone resorption. RANKL also activates
mature osteoclasts and inhibits osteoclast apoptosis. OPG is
also a member of the TNF receptor superfamily, but unlike
other members of this superfamily, it lacks a transmembrane
domain. Acting as a soluble decoy receptor preventing the
binding of RANKL to RANK, OPG inhibits osteoclast dif-
ferentiation and activation, and, stimulates osteoclast apo-
ptosis. Studies have demonstrated OPG and RANKL to be
regulated by a number of hormones. Estrogen increases OPG
levels (3), whereas PTH, testosterone, IGF-I, and cortisol
(3–5) decrease levels of OPG.
Anorexia nervosa (AN) is associated with extensive and
prevalent bone loss such that osteopenia has been reported
in 92%, and osteoporosis in as many as 38% of adult women
with this disorder (6, 7). In adult women with AN, an un-
coupling of bone turnover with decreased bone formation
and increased bone resorption is associated with low bone
density (8). Decreased bone mineral density (BMD) has been
identified in adolescent girls with AN at a time of maximal
bone accrual in normal girls (9–12). In girls with AN, we have
shown a decrease in markers of both bone formation and
bone resorption, suggesting a state of decreased bone turn-
over (11, 12). Therefore, underlying defects in bone metab-
olism may differ in AN depending on the age of the patients.
No studies to our knowledge have investigated serum OPG
levels in AN or determined the role of OPG in the bone loss
seen in adolescents with this disorder.
Critical hormonal factors that regulate OPG are disrupted
in AN due to profound undernutrition and are either un-
dersecreted (IGF-I, estrogen, and testosterone) or overse-
creted (cortisol). Low bone density has been demonstrated to
correlate with markers of nutritional status including body
mass index (BMI) (9, 13), lean body mass (10–12, 14), and fat
mass (10). Very low levels of IGF-I occur in AN as a conse-
quence of undernutrition, and markers of bone formation
correlate with levels of IGF-I (11, 15). In addition, hypotha-
lamic hypogonadism results in low levels of estrogen and
free testosterone (11, 12, 16). Hypercortisolemia has been
reported in adult women with AN (17–19), although this has
not been consistently observed in adolescents with this dis-
order (11, 12, 15). These hormonal alterations likely contrib-
ute to the low bone mass that is characteristic of AN. How-
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ever, the effects of these hormonal changes on serum OPG
levels in AN are yet to be determined.
To better understand underlying mechanisms of low bone
mass in adolescents with AN, we 1) determined levels of
OPG in adolescent girls with AN with and without osteope-
nia and in healthy controls of similar age and pubertal stage;
and 2) investigated the relationship of OPG levels to bone
density and markers of bone turnover.
Subjects and Methods
Subjects
We studied 43 Caucasian girls with AN and 38 healthy Caucasian
girls. Bone density, hormonal data, and biochemical data, with the
exception of OPG values, from 18 AN and 19 controls have been reported
previously (12). Girls with AN met the Diagnostic and Statistical
Manual-IV (revised) criteria for AN and ranged in age from 12.8–18.7
yr. Eight girls were premenarchal, and 35 girls had secondary amen-
orrhea. Girls with a history of intake of estrogen or other medications
known to affect bone metabolism within 3 months of study initiation
were excluded from the study. No girl had any condition other than AN
known to affect bone metabolism. Girls with AN were recruited through
mass mailings to physicians, nutritionists, and therapists in the Boston
area, and through referrals from Eating Disorder centers in New En-
gland. The control population ranged in age from 12.1–18.0 yr. Six were
premenarchal, and 32 were postmenarchal. None of the controls were
receiving medications or had medical conditions known to affect bone
metabolism. Controls were recruited through postings in offices of pri-
mary care providers and advertisements in Massachusetts General Hos-
pital and affiliated clinics. The study was approved by the institutional
review board of our hospital, and informed consent was obtained from
all subjects and their parents.
Experimental protocol
Subjects were screened at an initial visit to the General Clinical Re-
search Center of Massachusetts General Hospital, and eligibility was
determined based on history, physical examination, and laboratory re-
ports, which included potassium, glucose, LH, FSH, TSH, prolactin, and
a hematocrit. Eligible patients underwent a repeat medical and men-
strual history and a physical examination at the time of the study visit.
Healthy postmenarchal girls were studied in the early follicular phase
(d 1–7) of their menstrual cycles to control for effects of changing levels
of gonadal steroids across a menstrual cycle. Tanner staging for pubic
hair was performed for all subjects. In addition, blood was drawn in the
fasting state, and a second morning 2-h urine sample (for assessing
markers of bone resorption) was collected. Subjects also brought in a
24-h urine collection for estimation of urinary free cortisol, and a com-
pleted 4-d food diary, as per instructions provided at the time of the
screen. Each subject had a bone density test, and bone age (BA) deter-
mination was made.
Methods
Anthropometric measurements and pubertal staging. Subjects were weighed
in a hospital gown on an electronic scale after an overnight fast. Heights
were obtained in triplicate on a single stadiometer and averaged. BMI
percentiles were obtained from Centers for Disease Control and Pre-
vention 2000 charts (20). Subjects with AN and controls were matched
for pubertal stage and for BA to control for changes in bone density and
in bone markers that occur through puberty. BA was determined using
the methods of Greulich and Pyle (21). BA is highly correlated with
pubertal maturation and is delayed in conditions of undernutrition and
hypogonadism. Girls with a BA less than 15 yr were determined to be
immature for pubertal stage, whereas those with a BA 15 yr or older were
determined to be mature for pubertal stage.
Tanner breast stage is often difficult to determine in this population
because of associated breast atrophy. Many adolescents with AN go
through puberty at a normal age and therefore have had full pubertal
maturation before onset of AN. In such cases, although breast tissue
appears immature, BA may be mature due to the past exposure to sex
steroids and normal nutrition. This is a different physiological state than
an adolescent who develops AN early in development and has both
immature breast tissue and delayed BA. We therefore used pubic hair
rather than breast development to determine pubertal (Tanner) stage.
Girls in Tanner stages I, II, and III were classified as being in early
puberty, whereas those in Tanner stages IV and V were classified as
being in late puberty.
Laboratory analyses. OPG levels were measured by Amgen, Inc. (Thou-
sand Oaks, CA), using their in-house human endogenous OPG ELISA.
This assay uses mouse monoclonal antibody for capture and a rabbit
polyclonal antibody for detection. Reported OPG values include mo-
nomeric and dimeric forms of OPG, and OPG bound to RANKL. The
assay has a minimum detection limit of 2.34 pg/ml. Between test co-
efficients of variation (CV) using control sera are 0.91% (60.00 pg/ml),
1.57% (40.00 pg/ml), 0.69% (15.00 pg/ml), 1.82% (7.50 pg/ml), 2.7% (3.75
pg/ml), and 2.64% (2.34 pg/ml).
Serum osteocalcin (OC) was measured by an immunoradiometric
assay (Nichols Institute Diagnostics, San Juan Capistrano, CA). This
assay had a minimum detection limit of 0.5 g/liter and an intraassay
CV of 3.5–5.2%. ELISAs were used to determine levels of bone-specific
alkaline phosphatase (BSAP) (Quidel, Inc., Mountain View, CA, sensi-
tivity 0.7 U/liter, CV 3.9–5.8%), N-telopeptide (NTX) (Ostex Interna-
tional, Inc., Seattle, WA; limit of detection 20 nmol bone collagen equiv-
alent (BCE), CV 5–19%) and deoxypyridinoline (DPD) (Quidel, Inc.; limit
of detection 1.1 nmol/liter, CV 4.3–8.4%)
Estradiol levels were measured by ultrasensitive RIA (Diagnostic
Systems Laboratories, Inc., Webster, TX). The detection limit of this assay
is 2.2 pg/ml with a CV of 6.5–8.9%. We also used RIA to measure free
testosterone (DiaSorin, Inc., Stillwater, MN; detection limit 0.18 pg/ml,
intraassay CV 3.7–6.2%), serum dehydroepiandrosterone sulfate
(DHEAS) (Coated Tube RIA, DiaSorin, Inc.; detection limit 1.1g/dl and
intraassay CV 3.8–5.3%) and serum leptin (Linco Diagnostics, St. Louis,
MO; sensitivity 0.5 ng/ml and intraassay CV 3.4–8.3%). Serum IGF-I
was measured using an acid-alcohol extraction and RIA kit (Nichols
Institute Diagnostics; detection limit 0.06 ng/ml, intraassay CV 2.4–
3.0%). We measured serum IGF binding protein-3 (IGFBP-3) using an
immunoradiometric assay (Coated Tube IRMA, Diasorin, Inc.) with a
detection limit of 0.5 ng/ml and an intraassay CV of 1.8–3.9%. Free
testosterone, IGFBP-3, and DHEAS values were available in 21 AN and
22 controls.
Serum was frozen and stored at 80 C, and all assays were run in
duplicate.
Bone density measurements
Lumbar BMDs (LBMDs) were measured using a QDR-4500 dual
energy x-ray absorptiometer (Hologic, Inc., Waltham, MA). The sd for
lumbar spine BMD is 0.01 g/cm2 and does not vary with bone density.
z-Scores were calculated from the applet of Bachrach, Hastie, and
Narasimhan (http://www-stat-class.stanford.edu/pediatric-bones/)
for chronological age (CA) and BA. Although this applet is based on
measurements using a Hologic QDR 1000 bone densitometer, studies
have demonstrated very minimal differences in bone density measure-
ments at the lumbar spine using a Hologic QDR 4500 machine vs. a
Hologic QDR 1000 machine (r2  0.985 and 0.990, with mean BMD
differences of 0.68% and 0.003 g/cm2) (22, 23). Bone mineral apparent
density (BMAD), an estimate of volumetric bone density, was calculated
using the formula described by Katzman et al. (24).
Statistical analysis
All data are expressed as mean  sd. Student’s t test was used to
calculate differences between means in girls with AN and controls.
ANOVA was first used to perform a three group analysis comparing
girls with AN and low bone density (z-score  1) with girls with AN
whose BMD z-score was at least 1 and controls. When ANOVA was
significant, we performed the Tukey-Kramer’s test for comparisons
within all groups. Correlational and multiple regression analyses were
used to determine predictors of OPG levels and also to determine if OPG
predicted bone density and levels of bone turnover markers.
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Results
Demographic, body composition, and bone density data
Adolescent girls with AN and healthy controls had similar
CA (15.9  1.6 vs. 15.2  1.8 yr, P value not significant) and
BA (15.5  1.6 vs. 15.7  1.8 yr, P value not significant).
Twenty-three girls (13 AN and 10 controls) were pubertally
immature (based on BA), whereas 58 (30 AN and 28 controls)
had a mature BA. Twenty girls (12 AN and 8 controls) were
early pubertal (Tanner stages I–III), whereas 61 (31 AN and
30 controls) were late pubertal (Tanner stages IV and V). As
expected, weight, BMI, lean body mass, and percent fat mass
were all significantly lower in girls with AN than in controls
(weight: 45.2 5.2 vs. 59.0 10.3 kg, P 0.0001; BMI: 16.6
1.1 vs. 22.5  3.5 kg/m2, P  0.0001; lean body mass: 35.5 
4.0 vs. 38.7  5.8 kg, P  0.005, % fat mass 18.2  5.1 vs.
31.1 5.3%, P 0.0001). Compared with controls, girls with
AN had significantly lower LBMD z-scores for CA (0.94
0.98 vs. 0.23  0.49 g/cm2, P  0.0001) and BA (0.95 
0.85 vs.0.33 0.47 g/cm2, P 0.0002), and lumbar BMAD
(LBMAD) was also significantly lower in AN than in controls
(0.12  0.01 vs. 0.13  0.01 g/cm3, P  0.001). The mean
duration of amenorrhea in postmenarchal girls with AN was
11.7  10.2 months, whereas the mean duration since diag-
nosis of AN was 9.9  10.8 months.
Hormonal and bone turnover data
Significantly lower levels of IGF-I and leptin were seen in
the AN group compared with controls (IGF-I: 260  135 vs.
463 183 g/liter, P 0.0001; leptin: 3.2 2.3 vs. 13.7 6.0
g/liter, P  0.0001). Girls with AN had lower levels of
estradiol than healthy adolescents (54.7 21.3 vs. 70.9 23.0
pmol/liter, P  0.002). Value of free testosterone, DHEAS,
and urinary free cortisol did not differ in the two groups.
Levels of OC and BSAP, markers of bone formation, and of
DPD and NTX, markers of bone resorption, were lower in
girls with AN than in controls (OC: 39.6 23.9 vs. 55.9 32.5
g/liter, P  0.01; BSAP: 30.8  19.3 vs. 42.2  30.2 U/liter,
P  0.05; DPD: 9.5  4.0 vs. 14.2  10.9 nmol/mmol creat-
inine, P 0.01; NTX: 113 67 vs. 172 148 nmol BCE/mmol
creatinine, P  0.02).
In the whole group, leptin levels correlated positively with
lumbar spine BMD z-scores (r  0.42, P  0.0002) and
LBMAD (r 0.40, P 0.0003). Levels of IGF-I also correlated
positively with lumbar spine BMD z-scores (r  0.32, P 
0.005) and LBMAD (r  0.23, P  0.04). When multiple
regression analyses were performed with leptin, fat mass,
and lean body mass, significant predictors of lumbar spine
BMD z-scores were fat mass (accounting for 23% of the
variability) and lean body mass (accounting for 7% of the
variability), whereas fat mass was the only significant pre-
dictor of lumbar spine BMAD (accounting for 19% of the
variability). A positive correlation was observed between
levels of OC and lumbar spine BMD z-scores (r  0.24, P 
0.03). No correlations were noted between bone density z-
scores or BMAD and other markers of bone turnover,
IGFBP-3, free testosterone, DHEAS, or estradiol.
Serum OPG levels
Serum OPG levels were significantly higher in adolescents
with AN than in healthy adolescents (44.5  22.5 pg/ml vs.
34.5  12.7 pg/ml, P  0.02) (Fig. 1).
In a three-group analysis comparing OPG values in ado-
lescent girls with AN and low bone density z-scores (z1),
girls with AN and normal bone density z-scores (z1) and
controls (Table 1), OPG values were the highest in girls with
AN whose bone density z-scores were less than1, with the
values being significantly higher than in controls. Bone den-
sity measures, as expected, were significantly lower in this
group compared with the other two groups. This group also
had lower weight, BMI, lean body mass, and fat mass than
the control group. In addition, the ratio of BA/CA and levels
of OC, IGF-I, leptin, and estradiol were significantly lower in
this group than in controls. Girls with AN whose BMD z-
scores were at least 1 had OPG values intermediate be-
tween those in girls with AN and low bone density z-scores
and controls, but the value of OPG was not significantly
different from the other two groups. This group of girls with
AN also had lower mean weight, BMI, fat mass, ratio of
BA/CA, and levels of IGF-I, leptin, and estradiol than the
control group. Bone density measures in this group were not
different from those in healthy adolescents. The only differ-
ence in nutritional parameters that could account for differ-
ences in bone density measures in the two groups of ado-
lescent girls with AN was the lower lean body mass in the
group with the lower bone density z-scores. Free testoster-
one, DHEAS, and urinary free cortisol were not different in
the three groups.
In the whole group, a significant correlation was observed
between OPG and BMI (r  0.27, P  0.02), and OPG and
percent fat mass (r  0.35, P  0.002), such that girls with
the lowest BMI and lowest fat mass had the highest levels of
OPG. No correlation existed between levels of OPG and lean
body mass. An inverse correlation was also observed be-
tween leptin levels and serum OPG (r  0.28, P  0.02). In
a stepwise regression model including BMI, percent fat mass,
and leptin, percent fat mass was the only significant predictor
of serum OPG values, contributing to 13% of the variation in
serum OPG values. No correlation was observed between
OPG and other hormonal parameters (IGF-I, IGFBP-3, estra-
diol, free testosterone, or urinary free cortisol).
FIG. 1. OPG values in girls with AN and BA-matched controls. Girls
with AN had significantly higher OPG values than controls (44.5 
22.5 vs. 34.5  12.7, P  0.02).
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A negative correlation was noted between LBMD and
OPG levels (r0.22, P 0.05), LBMD z-scores (for CA) and
OPG (r0.25, P 0.03), and LBMAD and OPG (r0.26,
P  0.03) (Fig. 2, A and B). When the two outliers were
excluded, the correlation coefficient was0.33, P 0.004 for
LBMD, and 0.29, with a P value of 0.01 for LBMD z-scores
and BMAD. Conversely, markers of bone turnover did not
correlate with serum OPG values.
No correlation was observed between OPG and CA, and
no difference was noted between OPG levels in girls with
immature BA (BA 15 yr, n 23) vs. girls of mature BA (BA
 15 yr, n  58). However, a negative correlation was ob-
served between OPG and the ratio of BA to CA (BA/CA) (r
0.24, P  0.03) (Fig. 3). With exclusion of the same two
outliers described above, the correlation coefficient was
0.31, and the P value 0.008. BA/CA correlated positively
with LBMD z-scores (r  0.38, P  0.0005). Because delayed
puberty and lower BA/CA would be expected in girls with
lower bone density z-scores, we performed multiple regres-
sion analysis including lumbar bone density z-scores and the
ratio of BA/CA, and the latter was no longer a significant
predictor of OPG values. No differences were observed be-
tween OPG values in girls in early vs. late puberty (by pubic
hair staging).
In healthy controls taken alone, OPG correlated negatively
with percent body fat (r  0.34, P  0.04) and there was a
trend toward a negative correlation with LBMAD (r0.30,
P  0.06). A positive trend was observed between values of
IGFBP-3 and OPG (r  0.43, P  0.07) and a stronger cor-
relation between free testosterone values and OPG (r 0.50,
P  0.03). On stepwise regression, free testosterone values
contributed to 25% of the variability in OPG values, whereas
FIG. 2. Correlation between OPG values and LBMD z-scores and
LBMAD. A negative correlation was noted between OPG values and
LBMD z-scores (r  0.25, P  0.03) and with LBMAD (r  0.26,
P  0.03).
TABLE 1. Comparison of demographic, bone density, bone turnover, and hormonal characteristics in girls with AN and lumbar BMD
z-scores  1 and  1 and controls
AN with lumbar
BMD z  1
(n  20)
AN with lumbar
BMD z  1
(n  23)
Healthy
controls
(n  38)
ANOVA P
Age (yr) 15.5  1.6 16.2  1.6 15.2  1.8 ns
BA (yr) 15.2  1.6 15.7  1.6 15.7  1.8 ns
BA/CA 0.98  0.05a 0.97  0.04a 1.03  0.05 0.0001
Weight (kg) 47.7  6.0a 43.0  3.3a,b 59.0  10.3 0.0001
BMI (kg/m2) 17.0  1.1a 16.2  0.9a 22.5  3.5 0.0001
Lean body mass (kg) 37.0  4.5 34.1  3.0a 38.7  5.8 0.003
% Fat mass 18.6  5.5a 17.8  4.7a 31.1  5.3 0.0001
Lumbar (AP) BMD (g/cm2) 0.97  0.08 0.83  0.07a,b 0.96  011 0.0001
Lumbar (AP) BMD z-score (CA) 0.22  0.47 1.63  0.61a,b 0.23  0.49 0.0001
Lumbar (AP) BMD z-score (BA) 0.15  0.52 1.46  0.67a,b 0.33  0.47 0.0001
Lumbar (AP) BMAD 0.13  0.01 0.11  0.01a,b 0.13  0.01 0.0001
OPG (pg/ml) 41.6  21.8 46.9  23.2a 34.5  12.7 0.04
Osteocalcin (g/liter) 42.2  26.6 37.5  21.9a 55.9  32.5 0.04
Bone-specific AP (U/liter) 31.4  17.7 30.3  20.8 42.2  30.2 ns
N-telopeptide (nmol BCE/mmol cr) 114  53 112  78 172  148 0.08
Deoxypyridinoline (nmol/mmol cr) 9.3  4.2 9.7  4.0 14.2  10.9 0.05
IGF-I (g/liter) 277  160a 247  114a 463  183 0.0001
Leptin (g/liter) 3.3  2.1a 3.1  2.4a 13.7  6.0 0.0001
Estradiol (pmol/liter) 53.0  20.3a 56.4  22.0a 70.9  23.0 0.007
Free testosterone (pmol/liter)c 5.5  1.0 6.9  2.7 7.9  3.4 ns
DHEAS (mmol/liter)c 3.9  2.3 4.3  1.2 4.9  2.9 ns
Urinary free cortisol (g/d) 43.1  29.4 36.5  20.2 41.4  22.1 ns
Mean  SD.
ns, Not significant; AP, alkaline phosphatase; cr, creatinine.
a Significantly different from controls; b significantly different from AN with lumbar BMD z  1.
c Data available for 21 AN and 22 controls.
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IGFBP-3 contributed to 5% of this variability. These corre-
lations were not observed in girls with AN.
Discussion
Our data indicate higher levels of serum OPG in adoles-
cent girls with AN than in BA-matched controls, and a neg-
ative correlation between OPG and markers of nutritional
status, including BMI, fat mass, and leptin. In particular, girls
with AN and low bone density had higher OPG values than
did controls, whereas OPG values in girls with AN and
normal bone density z-scores did not differ from that in
controls. OPG levels correlated inversely with lumbar spine
bone density z-scores. Estrogen and urinary free cortisol did
not predict OPG levels, whereas a positive correlation was
observed between free testosterone and OPG in healthy ad-
olescents. We found that, in normal adolescents, OPG levels
were comparable in early and late puberty.
OPG levels have been demonstrated to be higher in os-
teoporotic postmenopausal women than in nonosteoporotic
postmenopausal women (25), though not consistently (26).
Levels have been shown to be higher in menopausal women
than in younger women despite lower estrogen levels in
postmenopausal women. It has been suggested that this may
be a compensatory response to bone loss, with the higher
OPG levels subsequently reducing osteoclast differentiation
and activation and increasing osteoclast apoptosis. Consis-
tent with this is the finding that administration of a single
3-mg/kg sc dose of OPG decreased levels of NTX by 80% in
postmenopauasal women (27). Adolescent girls with AN
have been demonstrated to have decreased bone turnover
with a decrease in markers of both bone formation and bone
resorption (12). The decrease in markers of bone resorption
may reflect the suppressive effects of higher OPG levels on
osteoclastic activity in this population. If this were so, how-
ever, one would expect low levels of bone resorption markers
in postmenopausal women with osteoporosis, and this has
not been reported. In our study, a negative correlation was
noted between lumbar spine BMD z-scores and OPG, and
LBMAD and OPG, suggesting that higher OPG values in
girls with lower BMD may indeed be a compensatory phe-
nomenon. However, like Ueland et al. (28), we did not find
a significant association between OPG and markers of bone
resorption.
We noted higher OPG levels in girls with lower BMI, fat
mass, and leptin levels. In particular, fat mass was an im-
portant predictor of serum OPG values. This may again
reflect a compensatory response because girls with AN have
significant decreases in body fat (10, 11), and the greatest
decreases in fat mass are seen in girls with the lowest weights
and BMIs. Girls with the lowest BMIs are also more likely to
suffer bone loss (9, 10). However, a decrease in lean body
mass is a more important predictor of bone loss than is a
decrease in BMI or fat mass (10, 11), and no correlations were
observed between lean body mass and serum OPG values in
this study. This finding was unexpected in that girls with AN
and low bone density z-scores differed from girls with AN
and normal bone density z-scores only in their mean lean
body mass, which was significantly lower than that in con-
trols, whereas lean body mass in girls with AN and normal
bone density z-scores was comparable to that in controls.
These data suggest a role for fat mass possibly independent
of bone loss in regulating levels of serum OPG, or that a
larger number of patients may be necessary to detect
significances.
The inverse relationship noted between levels of OPG and
leptin is also of interest in the light of recent data suggesting
an independent role for leptin in predicting BMD in post-
menopausal women (29). These authors demonstrated a pos-
itive correlation between leptin and femoral neck BMD, and
a negative correlation between leptin and bone resorption
markers, suggesting that leptin levels may inhibit the in-
creased bone resorption that is characteristic of postmeno-
pausal osteoporosis. In this study, we likewise observed a
positive correlation between leptin and bone density z-scores
and BMAD, though these significances were lost on multiple
regression analyses including fat mass and lean body mass.
Leptin has also been shown to stimulate human osteoblastic
cell proliferation and mineralization (30) and to inhibit os-
teoclast generation from human peripheral blood mononu-
clear cells (31). However, these studies demonstrated a local
increase in OPG levels following administration of leptin to
cell cultures (30, 31). We did not observe any correlations
between leptin levels and markers of bone turnover, and we
noted a negative correlation between leptin and OPG levels
in our study.
Serum OPG is regulated by many hormones including
estrogen, testosterone, PTH, cortisol, GH, and IGF-I. In this
study, lower levels of estrogen and IGF-I and a trend toward
lower levels of free testosterone were observed in girls with
AN than in matched controls, whereas urinary free cortisol
values were not different in the two groups. Estradiol values
were lower in both groups of girls with AN compared with
controls, irrespective of bone density status. Because estra-
diol increases OPG production by osteoblasts, decreased es-
tradiol secretion would be expected to result in decreased
production of OPG. Conversely, in this study, girls with AN
had low estradiol and high OPG levels, and we found no
correlation between OPG and estradiol values, similar to a
report by Khosla et al. (32). However, unlike Khosla et al. (32),
we did find a positive correlation between free testosterone
values and OPG in our healthy controls. One possible reason
for the lack of an association between estradiol and OPG
values is that we measured circulating rather than local OPG.
FIG. 3. Correlation between OPG values and the ratio of BA to CA
(BA/CA). A negative correlation was observed between OPG values
and BA/CA (r  0.24, P  0.03).
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In addition, our healthy subjects were studied in the early
follicular phase of their menstrual cycles when estradiol val-
ues are at a physiological nadir. These nadir values do not
reflect estradiol values at other stages of the menstrual cycle,
and it cannot be determined from this study if OPG values
are affected by net estradiol effects over a menstrual cycle as
opposed to nadir values measured in this study.
High cortisol values have been reported in adult women
with AN (17–19), and glucocorticoid excess has been dem-
onstrated to result in increased serum OPG (28). In our study,
as in other studies examining adolescent girls with AN (12,
15), urinary free cortisol values were not higher in AN girls
compared with controls, and we did not find an association
between cortisol values and OPG. Therefore, hypercortisol-
emia is unlikely to be an important mechanism of bone loss
in adolescents with AN. We noted a weak association be-
tween IGFBP-3 levels and OPG values in controls, but not in
anorectic subjects. No relationship was observed between
serum IGF-I and OPG values, similar to findings of Ueland
et al. (28). Data on the effects of administration of GH and
IGF-I on OPG production are conflicting, with reports of both
an increase in local OPG production following recombinant
human GH administration (33), and a decrease in OPG
values following administration of recombinant human
IGF-I (4).
In our subjects, a negative correlation was noted between
the ratio of BA to CA and OPG values, suggesting a role for
pubertal maturation on OPG levels. More mature adoles-
cents, however, have higher levels of estrogen and would
therefore be expected to have higher levels of OPG. Alter-
natively, bone turnover is greater in the early adolescent
years and decreases in late adolescence (34), and the higher
OPG values at a younger BA may reflect a compensatory
response to the extensive bone remodeling occurring in
younger adolescents. The lack of this extensive remodeling
in both mature and immature adolescents with AN (char-
acterized by a low bone turnover state), may explain why this
negative correlation with the ratio of BA to CA was not
observed in subjects with AN taken alone. Changes in body
fat distribution with pubertal maturation may also contrib-
ute to lower serum OPG values with increasing pubertal
maturity. However, in this study, leptin levels and percent
fat mass correlated positively with the ratio of BA to CA. In
addition, BA/CA was not a significant predictor of OPG
values on multiple regression analysis including LBMD z-
scores, suggesting that the association of pubertal maturation
and OPG values might merely reflect the delayed skeletal
maturation expected in girls with AN with lower bone den-
sity z-scores.
A confounder to this study is that we measured circulating
OPG rather than OPG produced locally in bone, and serum
levels may not accurately reflect local production of OPG in
bone. It would also be useful to measure levels of RANKL
and the ratio of OPG to RANKL. Currently available serum
assays for RANKL, however, have not been verified to rep-
resent bone turnover.
We thus demonstrate higher OPG values in adolescent
girls with AN and low bone density z-scores than in controls,
possibly subsequent to a compensatory response to the lower
bone density seen in this population. We also show a neg-
ative correlation of OPG with markers of nutritional status,
especially with fat mass, and with maturity, as determined
by the ratio of BA to CA. In healthy adolescents, OPG cor-
relates positively with testosterone values. Studies with
larger numbers of adolescents are necessary to confirm a
decrease in OPG levels with increasing pubertal maturity.
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